FR940325-2-00076 FR940325-2-00041 National Institutes of Health National Institute of Allergy and Infectious Diseases; Opportunity for a Cooperative Research and Development Agreement (CRADA) for the Clinical Development of a Live, Attenuated Cold-Adapted Influenza Virus Vaccine(s) AGENCY: National Institutes of Health, PHS, HHS. ACTION: Notice. SUMMARY: The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health announces its intention to make available, to all interested and capable parties, information related to the clinical development of a live, attenuated cold-adapted influenza virus vaccine(s). Briefly, under IND 601 (Investigational New Drug # ), the NIAID has supported the clinical research development of this experimental vaccine(s). The NIAID is interested in having these efforts utilized for the public good by transferring this information to a company with an interest in the development and licensure of the cold-adapted vaccine. The information in the IND 601 will be available for confidential evaluation to interested and capable parties for a period of 45 days. This information will be made available to representatives of companies at a site in Bethesda, Maryland, following the execution of a Confidentiality Agreement. Copies of the material may be made at this site, by company representatives, at a nominal fee to cover copying cost. Following this 45 day evaluation period, the NIAID will entertain proposals from any companies interested in pursuing the development of this product, for a period not to exceed 30 days. Scheduling for review of documents will occur on a first come, first serve basis but only after receipt of an executed Confidentiality Agreement. ADDRESSES: Proposals should be submitted to: Technology Transfer Branch, National Institute of Allergy & Infectious Diseases, National Institutes of Health, Bldg. 31, rm. 7A32, 9000 Rockville Pike, Bethesda, MD 20892. If you are interested in obtaining a copy of the Confidentiality Agreement and arranging for an appointment, please contact Dr. Carole Heilman, Chief, Respiratory Disease Branch, National Institute of Allergy & Infectious Diseases, National Institutes of Health, Solar Building, 6003 Executive Blvd., room 3B06, Rockville, Maryland, 20852, or telephone 301&hyph;496&hyph;5305. DATES: Proposals must be submitted on or before April 25, 1994. Dated: March 7, 1994. Donald P. Christoferson, Acting Director, Office of Technology Transfer, National Institutes of Health. [FR Doc. 94&hyph;7033 Filed 3&hyph;24&hyph;94; 8:45 am] BILLING CODE 4140&hyph;01&hyph;M
